Specialty Pharmacy

Study suggests that covering high-value medications benefits patients at no extra cost to insurers.

Researchers aim to determine whether an annual brain volume loss rate of less than 0.4% is a valid marker to assess treatment response.

Top news of the day from across the health care landscape.

The discontinuation of opioid therapy may address the rising death toll caused by drug overdoses while maintaining or potentially improving chronic, non-cancer pain in patients, according to a recent study.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses how to boost prescriber uptake of biosimilars.

Cognitive impairment is present in up to 70% of patients with multiple sclerosis, but can be difficult to completely evaluate in routine clinical practice.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The FDA has issued disease-specific draft guidances for the development of gene therapies for certain conditions.

A look at last week's top stories in the world of pharmacy.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Research to explore whether intermittent fasting can improve symptoms in patients with relapsing-remitting multiple sclerosis.

Olaparib (Lynparza, Merck and AstraZeneca) demonstrated significant improvement in progression-free survival in the first-line maintenance setting for women with advanced BRCA-mutated ovarian cancer.

Top news of the day from across the health care landscape.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

Even as fewer patients are using them, the 10 medications with the highest spend in Medicare Part D have seen substantial increases in spending and out-of-pocket costs.

Results from a phase 3 study and post-hoc analysis highlight the use of galcanezumab-gnlm (Emgality, Eli Lilly) for the treatment of episodic cluster headache and migraine.

The updated labeling will strengthen warnings for mental health adverse effects and risks related to hypoglycemia.

Top news of the day from across the health care landscape.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

Pharmaceutical manufacturers depend on hubs to act as connectors between various stakeholders across the specialty drug prescribing process.

The PALOMA-3 trial evaluated palbociclib (Ibrance) in combination with fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

The American Journal of Medicine has published a new article that describes the reemergence of neurosyphilis and identifies HIV coinfection in individuals in Western countries as a key risk factor.

A new, inexpensive diagnostic test can help identify patients who require immediate treatment for hepatitis B virus across Africa.

Top news of the day from across the health care landscape.

Multiple sclerosis risk increased significantly in individuals with occupational exposure to organic solvents.

Luis Torres, MBA, Vice President, Managed Care, BioPlus Specialty Pharmacy, speaks about why data is a crucial component of choosing a specialty pharmacy.

Researchers have developed a laser-sonic scanner with the ability to detect tumors in as little as 15 seconds.